Kymera Therapeutics

Kymera Therapeutics is a publicly traded operating company, not an investment fund, so capital allocation decisions are made by its management team and board of directors. Founder Nello Mainolfi serves as President and CEO and sets the R&D strategy. The board includes co-founder Bruce Booth of Atlas Venture, who has significant influence on strategic partnerships and financing.

Kymera identifies new protein-degradation targets through its proprietary Pegasus platform, which integrates computational biology, medicinal chemistry, and proteomics to design heterobifunctional degraders. The platform identifies E3 ligases and creates small molecules that bridge the target protein to the ligase. Candidates are then advanced through internal preclinical development before entering human trials.

In July 2020, Kymera and Sanofi entered a multi-program collaboration to develop degraders against oncology and immunology targets, with Kymera receiving a $150 million upfront payment. The deal excluded Kymera's lead programs in IRAK4 and STAT3. Sanofi retains rights to programs beyond those two targets, with Kymera eligible for significant milestones and royalties.

Kymera concentrates on oncology and immunology, with its most advanced programs targeting IRAK4 for inflammatory skin disease and STAT3 for blood cancers. The firm has signaled expanding interest in Th2-mediated immunology indications through its STAT6 degrader program. It does not currently pursue metabolic, cardiovascular, or central nervous system indications.

Targeted protein degradation uses a cell's natural ubiquitin-proteasome system to destroy disease-causing proteins entirely, rather than just blocking their active sites. Because a single degrader molecule can eliminate multiple target proteins, it operates at sub-stoichiometric levels — a catalytic mechanism that traditional small-molecule inhibitors cannot achieve. This allows targeting of proteins previously considered undruggable.

Kymera is capitalized through public equity markets following its August 2020 initial public offering on Nasdaq under the ticker KYMR. Prior to its IPO, the firm raised venture capital from Atlas Venture, Novartis, Pfizer, and other biotech crossover investors. As a clinical-stage biotech, it funds operations through partnership revenue, equity offerings, and existing cash reserves.

Kymera has demonstrated openness to strategic partnerships while protecting its core wholly owned programs. The Sanofi deal excluded IRAK4 and STAT3. The firm reacquired global rights to IRAK4 outside oncology from Sanofi in March 2023, indicating a preference for controlling assets it views as high-value. It has not publicly indicated intent to sell the company.